These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37515173)

  • 1. Inactivated and Immunogenic SARS-CoV-2 for Safe Use in Immunoassays and as an Immunization Control for Non-Clinical Trials.
    Gomes MPB; Linhares JHR; Dos Santos TP; Pereira RC; Santos RT; da Silva SA; Souza MCO; da Silva JFA; Trindade GF; Gomes VS; Barreto-Vieira DF; Carvalho MMVF; Ano Bom APD; Gardinali NR; Müller R; Alves NDS; Moura LDC; Neves PCDC; Esteves GS; Schwarcz WD; Missailidis S; Mendes YDS; de Lima SMB
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of SARS-CoV-2 inactivation by different chemical reagents on the humoral response evaluated in a murine model.
    de Castro Barbosa E; de Souza Andrade A; Duarte MM; Faria G; de Melo Iani FC; Ataide ACZ; Cunha LM; Duarte CG; Fialho SL; Caldas S
    Mol Immunol; 2022 Jul; 147():199-208. PubMed ID: 35644072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 5. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal Models of COVID-19: Transgenic Mouse Model.
    Park JG; Pino PA; Akhter A; Alvarez X; Torrelles JB; Martinez-Sobrido L
    Methods Mol Biol; 2022; 2452():259-289. PubMed ID: 35554912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.
    Abdoli A; Aalizadeh R; Aminianfar H; Kianmehr Z; Teimoori A; Azimi E; Emamipour N; Eghtedardoost M; Siavashi V; Jamshidi H; Hosseinpour M; Taqavian M; Jalili H
    Rev Med Virol; 2022 May; 32(3):e2305. PubMed ID: 34699647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.
    Gracheva AV; Korchevaya ER; Ammour YI; Smirnova DI; Sokolova OS; Glukhov GS; Moiseenko AV; Zubarev IV; Samoilikov RV; Leneva IA; Svitich OA; Zverev VV; Faizuloev EB
    Arch Virol; 2022 Nov; 167(11):2181-2191. PubMed ID: 35857146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.
    Kordyukova LV; Moiseenko AV; Serebryakova MV; Shuklina MA; Sergeeva MV; Lioznov DA; Shanko AV
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
    Roberts A; Lamirande EW; Vogel L; Baras B; Goossens G; Knott I; Chen J; Ward JM; Vassilev V; Subbarao K
    Viral Immunol; 2010 Oct; 23(5):509-19. PubMed ID: 20883165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
    Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.
    Radvak P; Kwon HJ; Kosikova M; Ortega-Rodriguez U; Xiang R; Phue JN; Shen RF; Rozzelle J; Kapoor N; Rabara T; Fairman J; Xie H
    Nat Commun; 2021 Nov; 12(1):6559. PubMed ID: 34772941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
    Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J
    Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
    Turan RD; Tastan C; Dilek Kancagi D; Yurtsever B; Sir Karakus G; Ozer S; Abanuz S; Cakirsoy D; Tumentemur G; Demir S; Seyis U; Kuzay R; Elek M; Kocaoglu ME; Ertop G; Arbak S; Acikel Elmas M; Hemsinlioglu C; Hatirnaz Ng O; Akyoney S; Sahin I; Kayhan CK; Tokat F; Akpinar G; Kasap M; Kocagoz AS; Ozbek U; Telci D; Sahin F; Yalcin K; Ratip S; Ince U; Ovali E
    Sci Rep; 2021 Aug; 11(1):15799. PubMed ID: 34349145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.
    Li ZX; Feng S; Zhang H; Zhuang XY; Shang C; Sun SY; Han JC; Xie YB; Zhang JY; Wang W; Li CH; Zhao GY; Hao PF; Ma JX; Gao Y; Zeng JQ; Tian MY; Ha Z; Lu HJ; Jin NY
    Arch Virol; 2022 Dec; 167(12):2519-2528. PubMed ID: 36083350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.